In this episode of MD Newsline, Dr. Sarimar Agosto Salgado, Oncologic Endocrinologist at Moffitt Cancer Center, shares insights from a panel discussion at the AACE 2025 conference on the complexities of advanced thyroid cancer. She explores case-based approaches to recurrent, radioactive iodine-refractory disease and introduces the evolving strategy of re-differentiation therapy—a promising method for resensitizing tumors to radioactive iodine.

Dr. Salgado also highlights real-world challenges including diagnostic errors, late referrals, and the need for greater access to multidisciplinary care.

Episode Highlights:

Understanding Radioactive Iodine-Refractory Disease

Dr. Salgado explains that a subset of thyroid cancer patients no longer respond to radioactive iodine due to disease progression. For these patients, careful monitoring, local therapies like SBRT, or systemic treatments become necessary depending on the tumor's growth and location.

Re-differentiation Therapy Explained

She introduces re-differentiation—a technique using short-term targeted therapy (e.g., BRAF inhibitors) to restore the tumor's ability to uptake radioactive iodine. This allows for additional rounds of treatment and may delay or reduce the need for long-term systemic therapy.

The Role of Real-World Data and Registries

Because prospective clinical trials remain limited, Dr. Salgado advocates for collecting data through real-world registries and academic collaborations. These efforts may help define optimal timing, predictive markers, and response indicators for re-differentiation therapy.

Challenges in Diagnosis and Timely Referral

Dr. Salgado reflects on misdiagnosed cases, including rare thyroid variants confused with neuroendocrine tumors. She emphasizes the importance of early referral to expert centers before treatment limits available options.

Access and Equity in Advanced Thyroid Cancer

Many patients lack access to high-volume thyroid teams, leading to missed opportunities. Dr. Salgado urges clinicians to prioritize expert pathology review, molecular testing, and full-neck imaging to avoid delays in diagnosis and care.

Key Takeaway:

Advanced thyroid cancer is complex and often underestimated. Early referral, precision strategies like re-differentiation, and equitable access to expert teams are critical to improving outcomes and expanding hope for patients with this challenging disease.

Resources & Links:

Website: MD Newsline

Newsletter: Subscribe

Connect with Dr. Sarimar Agosto Salgado: Here